361 related articles for article (PubMed ID: 30880359)
1. Relapsed T Cell ALL: Current Approaches and New Directions.
McMahon CM; Luger SM
Curr Hematol Malig Rep; 2019 Apr; 14(2):83-93. PubMed ID: 30880359
[TBL] [Abstract][Full Text] [Related]
2. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
DeAngelo DJ
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
[TBL] [Abstract][Full Text] [Related]
3. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
4. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
5. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
[TBL] [Abstract][Full Text] [Related]
6. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
[TBL] [Abstract][Full Text] [Related]
7. Therapy of Relapsed/Refractory Acute Lymphoblastic Leukemia Today and Tomorrow.
Hrabovský Š; Folber F; Doubek M
Klin Onkol; 2019; 32(2):90-96. PubMed ID: 30995847
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
Pocock R; Farah N; Richardson SE; Mansour MR
Br J Haematol; 2021 Jul; 194(1):28-43. PubMed ID: 33942287
[TBL] [Abstract][Full Text] [Related]
9. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
Luskin MR; Ganetsky A; Landsburg DJ; Loren AW; Porter DL; Nasta SD; Svoboda J; Luger SM; Frey NV
Br J Haematol; 2016 Jul; 174(2):332-4. PubMed ID: 26403537
[No Abstract] [Full Text] [Related]
10. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
Kathpalia M; Mishra P; Bajpai R; Bhurani D; Agarwal N
Ann Hematol; 2022 Aug; 101(8):1655-1666. PubMed ID: 35727338
[TBL] [Abstract][Full Text] [Related]
12. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
13. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia.
Patel J; Gao X; Wang H
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108359
[TBL] [Abstract][Full Text] [Related]
14. Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.
Thomas X; Le Jeune C
Expert Opin Pharmacother; 2016 Dec; 17(17):2319-2330. PubMed ID: 27759440
[TBL] [Abstract][Full Text] [Related]
15. Novel Approaches for the Interim Management of Relapsed/Refractory Acute Lymphocytic Leukemia: A Case-Study Compendium.
Wang ES; Jabbour EJ; Douer D
Clin Adv Hematol Oncol; 2016 Mar; 14(3 Suppl 4):1-23. PubMed ID: 27007406
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
17. The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Lato MW; Przysucha A; Grosman S; Zawitkowska J; Lejman M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925883
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
Ronson A; Tvito A; Rowe JM
Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
[TBL] [Abstract][Full Text] [Related]
19. Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
Fulcher J; Berardi P; Christou G; Villeneuve PJA; Bredeson C; Sabloff M
Leuk Lymphoma; 2021 Sep; 62(9):2295-2297. PubMed ID: 33749497
[No Abstract] [Full Text] [Related]
20. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
Evangelisti C; Evangelisti C; Chiarini F; Lonetti A; Buontempo F; Bressanin D; Cappellini A; Orsini E; McCubrey JA; Martelli AM
Int J Oncol; 2014 Sep; 45(3):909-18. PubMed ID: 24968804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
